https://trial.medpath.com/news/evolving-landscape-of-oncology-clinical-trials-expert-insights-on-precision-medicine-and-patient-recruitment 2014-07-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolving-landscape-of-oncology-clinical-trials-expert-insights-on-precision-medicine-and-patient-recruitment 2014-07-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/time-and-motion-studies-emerge-as-critical-tool-for-healthcare-efficiency-assessment 2014-07-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/time-and-motion-studies-emerge-as-critical-tool-for-healthcare-efficiency-assessment 2014-07-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/wales-launches-ps100-million-life-sciences-hub-to-boost-innovation-and-investment 2014-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wales-launches-ps100-million-life-sciences-hub-to-boost-innovation-and-investment 2014-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-hpv-dna-test-as-primary-cervical-cancer-screening-alternative-to-pap-smear 2014-04-25T01:41:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-hpv-dna-test-as-primary-cervical-cancer-screening-alternative-to-pap-smear 2014-04-25T01:41:58+00:00 weekly 0.7 https://trial.medpath.com/news/elevated-bone-turnover-markers-predict-poor-survival-in-castration-resistant-prostate-cancer 2014-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elevated-bone-turnover-markers-predict-poor-survival-in-castration-resistant-prostate-cancer 2014-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-strategies-for-patient-recruitment-in-rare-disease-trials-lessons-from-the-alkaptonuria-experience 2014-02-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-strategies-for-patient-recruitment-in-rare-disease-trials-lessons-from-the-alkaptonuria-experience 2014-02-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-clinical-trial-design-bridging-the-gap-between-regulatory-approval-and-market-access 2014-01-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strategic-clinical-trial-design-bridging-the-gap-between-regulatory-approval-and-market-access 2014-01-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oasis-diagnostics-receives-michael-j-fox-foundation-grant-for-saliva-based-parkinson-s-test 2014-01-10T04:38:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oasis-diagnostics-receives-michael-j-fox-foundation-grant-for-saliva-based-parkinson-s-test 2014-01-10T04:38:18+00:00 weekly 0.7 https://trial.medpath.com/news/poly-adp-ribose-polymerase-parp-inhibitors-for-the 2014-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poly-adp-ribose-polymerase-parp-inhibitors-for-the 2014-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-natural-killer-cell-cancer-immunotherapy 2014-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-natural-killer-cell-cancer-immunotherapy 2014-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/administration-of-the-etonogestrel-contraceptive-implant-on 2013-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/administration-of-the-etonogestrel-contraceptive-implant-on 2013-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rare-disease-research-faces-critical-funding-gap-despite-scientific-value 2013-10-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rare-disease-research-faces-critical-funding-gap-despite-scientific-value 2013-10-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-for-myelofibrosis-an-update-of-its-clinical-effects 2013-10-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruxolitinib-for-myelofibrosis-an-update-of-its-clinical-effects 2013-10-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-150-years-of-pharmaceutical-innovation-and-global-healthcare-leadership 2013-08-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-150-years-of-pharmaceutical-innovation-and-global-healthcare-leadership 2013-08-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-healthcare-reform-ambitious-1-trillion-investment-plan-reshapes-market-access-landscape 2013-07-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-s-healthcare-reform-ambitious-1-trillion-investment-plan-reshapes-market-access-landscape 2013-07-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-breakthroughs-in-hematologic-malignancies-expert-highlights-promising-treatments-and-research-directions 2013-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emerging-breakthroughs-in-hematologic-malignancies-expert-highlights-promising-treatments-and-research-directions 2013-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-s-strategic-approach-to-global-pharmacovigilance-balancing-innovation-with-patient-safety 2013-07-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-s-strategic-approach-to-global-pharmacovigilance-balancing-innovation-with-patient-safety 2013-07-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-complex-safety-evaluations-in-early-phase-cancer-drug-development 2013-07-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/navigating-complex-safety-evaluations-in-early-phase-cancer-drug-development 2013-07-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/italian-pharmaceutical-market-faces-1-6b-decline-as-government-pushes-generic-drug-adoption 2013-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/italian-pharmaceutical-market-faces-1-6b-decline-as-government-pushes-generic-drug-adoption 2013-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-market-access-hurdles-loom-for-pd-1-pd-l1-immunotherapies-in-oncology 2013-06-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-market-access-hurdles-loom-for-pd-1-pd-l1-immunotherapies-in-oncology 2013-06-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rising-costs-and-success-rates-the-complex-economics-of-oncology-drug-development 2013-06-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rising-costs-and-success-rates-the-complex-economics-of-oncology-drug-development 2013-06-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-gives-update-on-the-clinical-development-of-its-lead-cancer 2013-05-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-gives-update-on-the-clinical-development-of-its-lead-cancer 2013-05-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-serono-and-quintiles-forge-groundbreaking-5-year-clinical-development-partnership 2013-05-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-serono-and-quintiles-forge-groundbreaking-5-year-clinical-development-partnership 2013-05-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-payers-show-flexibility-in-nebulizer-access-despite-limited-clinical-evidence-in-asthma-treatment 2013-04-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-payers-show-flexibility-in-nebulizer-access-despite-limited-clinical-evidence-in-asthma-treatment 2013-04-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/temozolomide-s-effectiveness-in-treating-high-grade-glioma 2013-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/temozolomide-s-effectiveness-in-treating-high-grade-glioma 2013-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-s-evolution-in-social-media-from-listening-to-collaboration-in-rare-disease-communities 2013-02-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-s-evolution-in-social-media-from-listening-to-collaboration-in-rare-disease-communities 2013-02-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/home-healthcare-services-emerge-as-strategic-priority-for-pharmaceutical-companies 2013-02-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/home-healthcare-services-emerge-as-strategic-priority-for-pharmaceutical-companies 2013-02-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-new-draft-guidance-for-early-stage-alzheimer-s-drug-development 2013-02-12T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-new-draft-guidance-for-early-stage-alzheimer-s-drug-development 2013-02-12T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-push-for-clinical-trial-transparency-gains-momentum-with-ema-and-alltrials-campaign 2013-01-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-push-for-clinical-trial-transparency-gains-momentum-with-ema-and-alltrials-campaign 2013-01-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-and-biological-e-form-joint-venture-to-develop-novel-six-in-one-pediatric-vaccine 2013-01-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-and-biological-e-form-joint-venture-to-develop-novel-six-in-one-pediatric-vaccine 2013-01-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cook-medical-s-zilver-ptx-becomes-first-fda-approved-drug-eluting-peripheral-stent-in-u-s-market 2013-01-16T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cook-medical-s-zilver-ptx-becomes-first-fda-approved-drug-eluting-peripheral-stent-in-u-s-market 2013-01-16T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-extended-release-diphenidol-formulation-reduces-dosing-frequency-while-maintaining-therapeutic-plasma-levels 2013-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-extended-release-diphenidol-formulation-reduces-dosing-frequency-while-maintaining-therapeutic-plasma-levels 2013-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-spin-outs-emerge-as-critical-bridge-between-academia-and-pharma-r-d 2012-12-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-spin-outs-emerge-as-critical-bridge-between-academia-and-pharma-r-d 2012-12-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-approval-of-selincro-for-alcohol-dependency-treatment 2012-12-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-recommends-approval-of-selincro-for-alcohol-dependency-treatment 2012-12-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emotional-marketing-in-pharma-evidence-shows-power-of-combining-rational-and-emotional-appeals 2012-11-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emotional-marketing-in-pharma-evidence-shows-power-of-combining-rational-and-emotional-appeals 2012-11-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-journey-from-vitamin-production-pioneer-to-personalized-medicine-leader 2012-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-journey-from-vitamin-production-pioneer-to-personalized-medicine-leader 2012-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/prucalopride-in-the-treatment-of-chronic-constipation 2012-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prucalopride-in-the-treatment-of-chronic-constipation 2012-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/suppl-1-a-reappraisal-of-the-u-s-clinical-trials-of-post-treatment 2012-10-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suppl-1-a-reappraisal-of-the-u-s-clinical-trials-of-post-treatment 2012-10-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-and-bristol-myers-squibb-restructure-alliance-following-patent-expirations 2012-10-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-and-bristol-myers-squibb-restructure-alliance-following-patent-expirations 2012-10-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-confirms-efficacy-of-ulipristal-acetate-as-emergency-contraception 2012-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-confirms-efficacy-of-ulipristal-acetate-as-emergency-contraception 2012-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-giants-embrace-open-science-pfizer-merck-lead-industry-transformation 2012-08-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-giants-embrace-open-science-pfizer-merck-lead-industry-transformation 2012-08-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nih-expert-outlines-critical-challenges-and-solutions-in-rare-disease-clinical-trials 2012-08-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-expert-outlines-critical-challenges-and-solutions-in-rare-disease-clinical-trials 2012-08-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-clinical-trial-outsourcing-could-save-pharma-industry-billions-experts-say 2012-07-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strategic-clinical-trial-outsourcing-could-save-pharma-industry-billions-experts-say 2012-07-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-clinical-trials-navigating-challenges-and-opportunities-in-modern-drug-development 2012-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-clinical-trials-navigating-challenges-and-opportunities-in-modern-drug-development 2012-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-biosimilars-market-set-to-reach-2-3-billion-by-2015-as-industry-faces-development-challenges 2012-04-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-biosimilars-market-set-to-reach-2-3-billion-by-2015-as-industry-faces-development-challenges 2012-04-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-treatment-doubles-skin-cancer-drug-s-effectiveness 2012-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-treatment-doubles-skin-cancer-drug-s-effectiveness 2012-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-biosimilars-market-set-to-reach-3-99-billion-by-2017-as-industry-embraces-complex-biologics 2012-03-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-biosimilars-market-set-to-reach-3-99-billion-by-2017-as-industry-embraces-complex-biologics 2012-03-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/india-s-complex-regulatory-landscape-poses-major-hurdles-for-pharmaceutical-approvals 2012-02-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-s-complex-regulatory-landscape-poses-major-hurdles-for-pharmaceutical-approvals 2012-02-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glucose-dependent-insulinotropic-polypeptide-reduces 2012-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glucose-dependent-insulinotropic-polypeptide-reduces 2012-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/obinutuzumab-shows-promise-in-treating-proliferative-lupus-nephritis-in-phase-2-trial 2012-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obinutuzumab-shows-promise-in-treating-proliferative-lupus-nephritis-in-phase-2-trial 2012-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/barriers-to-personalized-medicine-payer-reimbursement-challenges-slow-diagnostic-test-adoption 2011-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/barriers-to-personalized-medicine-payer-reimbursement-challenges-slow-diagnostic-test-adoption 2011-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-car-modified-t-cells-for-leukemia-treatment 2011-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-car-modified-t-cells-for-leukemia-treatment 2011-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xarelto-okayed-by-fda-for-treating-atrial-fibrillation-cbs-news 2011-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xarelto-okayed-by-fda-for-treating-atrial-fibrillation-cbs-news 2011-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lifestyle-and-metformin-interventions-show-significant-benefits-in-diabetes-prevention 2011-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lifestyle-and-metformin-interventions-show-significant-benefits-in-diabetes-prevention 2011-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/four-key-drivers-reshaping-successful-oncology-drug-launches-in-modern-market 2011-08-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/four-key-drivers-reshaping-successful-oncology-drug-launches-in-modern-market 2011-08-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-lung-cancer-screening-ct-scans-reduce-mortality 2011-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-lung-cancer-screening-ct-scans-reduce-mortality 2011-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lialda-for-maintenance-of-remission-in-ulcerative-colitis-patients 2011-07-18T15:41:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lialda-for-maintenance-of-remission-in-ulcerative-colitis-patients 2011-07-18T15:41:37+00:00 weekly 0.7 https://trial.medpath.com/news/cetuximab-enhances-treatment-efficacy-for-metastatic-colorectal-cancer-with-kras-wild-type 2011-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cetuximab-enhances-treatment-efficacy-for-metastatic-colorectal-cancer-with-kras-wild-type 2011-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/metallic-copper-as-an-antimicrobial-surface-a-comprehensive-review 2010-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metallic-copper-as-an-antimicrobial-surface-a-comprehensive-review 2010-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-pharmaceutical-r-d-outsourcing-trends-industry-shifts-toward-strategic-partnerships-and-offshore-operations 2010-09-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-pharmaceutical-r-d-outsourcing-trends-industry-shifts-toward-strategic-partnerships-and-offshore-operations 2010-09-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urovant-sciences-announces-u-s-fda-approval-of-gemtesa 2010-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urovant-sciences-announces-u-s-fda-approval-of-gemtesa 2010-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-economic-pressures-force-pharmaceutical-industry-to-confront-radical-transformation 2010-05-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-economic-pressures-force-pharmaceutical-industry-to-confront-radical-transformation 2010-05-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kras-mutation-in-stage-iii-colon-cancer-and-clinical-outcome-following-intergroup-trial-calgb-89803 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kras-mutation-in-stage-iii-colon-cancer-and-clinical-outcome-following-intergroup-trial-calgb-89803 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-access-to-investigational-drugs-for-treatment-use 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-access-to-investigational-drugs-for-treatment-use 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-sanofi-s-multaq-for-atrial-fibrillation-patients-marking-first-new-treatment-in-two-decades 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-sanofi-s-multaq-for-atrial-fibrillation-patients-marking-first-new-treatment-in-two-decades 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nz-scientist-s-gene-research-offers-hope-against-obesity-epidemic 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nz-scientist-s-gene-research-offers-hope-against-obesity-epidemic 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-guidance-for-cardiovascular-risk-assessment-of-novel-antidiabetic-agents 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-guidance-for-cardiovascular-risk-assessment-of-novel-antidiabetic-agents 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/wuxi-pharmatech-strengthens-board-with-strategic-appointments-of-industry-veterans 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wuxi-pharmatech-strengthens-board-with-strategic-appointments-of-industry-veterans 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-cancer-treatment-successes-identified-in-phase-3-trials 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-cancer-treatment-successes-identified-in-phase-3-trials 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ku-team-announces-breakthrough-in-leishmaniasis-treatment 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ku-team-announces-breakthrough-in-leishmaniasis-treatment 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-on-adherence-to-glaucoma-medication-regimens 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-on-adherence-to-glaucoma-medication-regimens 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-contraception-with-mifepristone 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekly-contraception-with-mifepristone 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/progress-and-challenges-in-developing-blood-stage-malaria-vaccines 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/progress-and-challenges-in-developing-blood-stage-malaria-vaccines 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/generalizability-in-two-clinical-trials-of-lyme-disease-pmc 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/generalizability-in-two-clinical-trials-of-lyme-disease-pmc 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-implantable-artificial-heart-gets-fdas-approval 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-implantable-artificial-heart-gets-fdas-approval 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-insights-into-bladder-cancer-screening-and-awareness-campaign-launch 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-insights-into-bladder-cancer-screening-and-awareness-campaign-launch 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/honorhealth-s-cancer-research-program-a-leader-in-clinical-trials-and-treatment-innovation 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/honorhealth-s-cancer-research-program-a-leader-in-clinical-trials-and-treatment-innovation 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-and-treatment-of-post-lyme-disease-stop-ld 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-and-treatment-of-post-lyme-disease-stop-ld 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-expanded-use-of-med-el-cochlear-implant-system 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-expanded-use-of-med-el-cochlear-implant-system 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/home-based-exercise-program-significantly-reduces-knee-pain-study-finds 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/home-based-exercise-program-significantly-reduces-knee-pain-study-finds 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-cphpc-drug-shows-promise-in-breaking-down-alzheimer-s-amyloid-clumps 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-cphpc-drug-shows-promise-in-breaking-down-alzheimer-s-amyloid-clumps 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/culturally-tailored-interventions-boost-cervical-cancer-screening-among-chinese-women-in-north-america 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/culturally-tailored-interventions-boost-cervical-cancer-screening-among-chinese-women-in-north-america 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-treatment-beating-ovarian-cancer 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-treatment-beating-ovarian-cancer 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-antithymocyte-globulin-therapy-enhances-survival-in-steroid-resistant-acute-gvhd-patients 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-antithymocyte-globulin-therapy-enhances-survival-in-steroid-resistant-acute-gvhd-patients 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/asco-2024-lenvatinib-plus-pembrolizumab-shows-superiority-over-sunitinib-in-advanced-renal-cell-carcinoma 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asco-2024-lenvatinib-plus-pembrolizumab-shows-superiority-over-sunitinib-in-advanced-renal-cell-carcinoma 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pembrolizumab-for-advanced-esophageal-squamous-cell-cancer-with-pd-l1-expression 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pembrolizumab-for-advanced-esophageal-squamous-cell-cancer-with-pd-l1-expression 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regional-chemotherapy-for-liver-metastases-of-colorectal-cancer-shows-varied-perfusion-patterns 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regional-chemotherapy-for-liver-metastases-of-colorectal-cancer-shows-varied-perfusion-patterns 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regional-chemotherapy-shows-promise-in-treating-colorectal-cancer-metastatic-to-the-liver 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regional-chemotherapy-shows-promise-in-treating-colorectal-cancer-metastatic-to-the-liver 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d3bio-s-novel-kras-g12c-inhibitor-shows-promising-results-in-phase-1-cancer-trial 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/d3bio-s-novel-kras-g12c-inhibitor-shows-promising-results-in-phase-1-cancer-trial 2010-01-01T00:00:00+00:00 weekly 0.7